Quantcast

Latest Diabetic foot Stories

2009-08-27 09:00:00

SAN DIEGO, Aug. 27 /PRNewswire-FirstCall/ -- Cardium Therapeutics (NYSE Amex: CXM) today reported that a recent medical journal article highlights the challenges facing healthcare providers with respect to finding optimal treatments for patients with non-healing wounds. (Logo: http://www.newscom.com/cgi-bin/prnh/20051018/CARDIUMLOGO) As reported in the Journal of the American Academy of Physician Assistants, (JAAPA, August 2009), chronic wounds affect an estimated 5.7 million patients...

2009-08-07 08:00:00

SKILLMAN, N.J., Aug. 7 /PRNewswire/ -- ConvaTec, a world-leading provider of innovative medical technologies for community and hospital care, today announced the launch of a new campaign and best practice statement supporting Versiva((R)) XC((R)) gelling foam dressing. Backed up by extensive in vivo and in vitro data, the new campaign shows how healthcare professionals can "Expect More" with Versiva((R)) XC((R)) dressing. The only cover dressing to contain ConvaTec's proprietary...

2009-07-28 08:00:00

SAN DIEGO, Calif., July 28 /PRNewswire-FirstCall/ -- Cardium Therapeutics (NYSE Amex: CXM) and its subsidiary Tissue Repair Company (TRC) today provided an update on the completion of their MATRIX Phase 2b clinical study and announced plans to provide detailed safety and efficacy data for their Excellarate(TM) product candidate around the end of September. The MATRIX trial, a prospective, randomized, double-blind, placebo-controlled study, has enrolled 124 diabetic patients with...

2009-07-07 08:30:00

FORT WORTH, Texas, July 7 /PRNewswire/ -- Wound Care Innovations, LLC, a subsidiary of Wound Management Technologies, Inc., (WNDM.ob), announced today that it will exhibit at the New Cardiovascular Horizons and Management of the Diabetic Foot & Wound Healing (NCVH) conference in New OrleansJuly 9-11. NCVH has become the largest multidisciplinary conference in the country, bringing together cardiologists, surgeons, podiatrists, wound care specialists, family practice physicians,...

2009-06-18 06:00:00

ASHBURN, Va., June 18 /PRNewswire/ -- Innocoll, Inc., a privately-held biopharmaceutical company, announced positive provisional findings from its three phase 2 clinical trials sponsored by its wholly owned subsidiary, Innocoll Technologies Ltd, to investigate CollaRx(R) GENTAMICIN TOPICAL for the treatment and prevention of infection in diabetic foot ulcers. Chronic ulcerations such as diabetic foot ulcers are often colonized or contaminated with bacterial pathogens that can prevent ulcers...

2009-05-26 09:28:03

Diabetes rates have risen sharply in developed countries in the wake of the obesity epidemic, and an estimated 30 million Europeans live with the condition. Foot problems are the most common cause of admission to hospital for diabetics, who are at risk of serious complications such as nerve damage and problems with the blood supply to their feet. Both conditions can lead to slow-healing wounds and foot ulcers which, if they get infected and become gangrenous, can lead to amputation. According...

2009-05-12 16:24:00

FARMINGDALE, N.Y., May 12 /PRNewswire-FirstCall/ -- Misonix, Inc. (Nasdaq: MSON), a developer of minimally invasive ultrasonic medical device technology, which in Europe is used for the ablation of tumors and worldwide for other acute health conditions, has announced their attendance and participation in the annual Diabetic Foot Global Conference (DFCON), which was held in Los Angeles, CA, March 19-21, 2009. In addition to exhibiting its SonicOne(R) Ultrasonic Wound Cleansing and Debridement...

2009-05-12 08:15:00

SAN DIEGO, May 12 /PRNewswire-FirstCall/ -- Cardium Therapeutics (NYSE Amex: CXM) today announced that the Company will hold a conference call and webcast to discuss recent developments and future plans for its Excellarate(TM) clinical development program. (Logo: http://www.newscom.com/cgi-bin/prnh/20051018/CARDIUMLOGO) On May 6, 2009, the Company announced the completion of recruitment for the Tissue Repair Company's pioneering gene therapy Phase 2b MATRIX clinical trial to evaluate the...

2009-05-07 08:00:00

SAN DIEGO, May 7 /PRNewswire-FirstCall/ -- Cardium Therapeutics (NYSE Amex: CXM) and its subsidiary Tissue Repair Company (TRC) today announced significant new formulation enhancements for its Excellarate(TM) product candidate that are designed to simplify and broaden the use of Excellarate for diabetic ulcers, and also expand the potential applicability into a number of additional wound healing market opportunities, including pressure and venous stasis ulcers, as well as major surgical and...

2009-05-06 16:37:00

SAN DIEGO, May 6 /PRNewswire-FirstCall/ -- Cardium Therapeutics (NYSE Amex: CXM) and its subsidiary Tissue Repair Company (TRC) today announced the completion of recruitment for the pioneering Phase 2b MATRIX clinical trial to evaluate the safety and efficacy of the Excellarate(TM) product candidate for the potential treatment of non-healing foot ulcers in patients with type I or type II diabetes. Excellarate is designed to require only one or two physician-administered treatments, in...


Word of the Day
bellycheer
  • Good cheer; viands.
  • To revel; to feast.
The word 'bellycheer' may come from 'belle cheer', "good cheer".
Related